J Korean Assoc Pediatr Surg.  2014 Dec;20(2):53-57. 10.13029/jkaps.2014.20.2.53.

Clinical Feature of Neonatal Neuroblastoma: Comparison of Outcome between Diagnosed Prenatally and at Postpartum Group

• Park HH
• Kim SH
• Jung SE
• Lee SC
• Park KW
• Lee JW
• Kang HJ
• Shin HY
• Baek HW
• Kim HY

• KMID: 1961487
• DOI: http://doi.org/10.13029/jkaps.2014.20.2.53

Abstract

PURPOSE
Neonatal neuroblastoma (NBL) is the most common malignant tumor in neonates, but there have been few studies about it. The purpose of this study was to investigate the clinical features of NBL and to compare prenatal and postnatal diagnosed groups.
METHODS
Nineteen patients who were diagnosed with NBL prenatally or within 28 days after birth from February 1986 to February 2013 in Seoul National University Hospital were enrolled in the study. The patients were categorized according to the International Neuroblastoma Staging System (INSS) and Children's Oncology Group (COG). Retrospective medical-record reviews were performed on these patients. The operative date, complication, pathological stage, and overall survival of the prenatally diagnosed group and the postpartum diagnosed group were compared.
RESULTS
Tumor was detected via prenatal ultrasonography in 8 patients (42.1%), and 11 patients (57.9%) were diagnosed within 28 days after birth. Based on INSS, the patients were divided into the stage I (n=8), stage II (n=1), stage III (n=3), stage IV (n=4), and stage IVs (n=3) groups, respectively. Based on COG, on the other hand, the patients were divided into the low-risk (n=8), intermediate-risk (n=8), and high-risk (n=3) groups. The postoperative complication rate was 29%. One patient died from complications from chemotherapy. The other 18 patients' mean follow-up period was 77.7 months. The differences between the postoperative complication rate, proportion of early-stage tumor, and overall survival of the prenatal and postnatal groups were not statistically significant (p=0.446, p=0.607, p=0.414).
CONCLUSION
NBL showed favorable outcomes but relatively higher postoperative complications. There seem to be no significant statistical differences in the postoperative complications, proportion of early-stage tumor, and overall survival between the prenatally diagnosed group and the postpartum diagnosed group.

Keyword

Neuroblastoma; Neonate; Prenatal diagnosis; Postpartum; Outcome

MeSH Terms

Drug Therapy
Follow-Up Studies
Hand
Humans
Infant, Newborn
Neuroblastoma*
Parturition
Postoperative Complications
Postpartum Period*
Prenatal Diagnosis
Retrospective Studies
Seoul
Ultrasonography, Prenatal

Reference

1. Mullassery D, Dominici C, Jesudason EC, McDowell HP, Losty PD. Neuroblastoma: contemporary management. Arch Dis Child Educ Pract Ed. 2009; 94:177–185.

2. Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature. 1983; 305:245–248.

3. Coldman AJ, Fryer CJ, Elwood JM, Sonley MJ. Neuroblastoma: influence of age at diagnosis, stage, tumor site, and sex on prognosis. Cancer. 1980; 46:1896–1901.

4. Schmidt ML, Lukens JN, Seeger RC, Brodeur GM, Shimada H, Gerbing RB, et al. Biologic factors determine prognosis in infants with stage IV neuroblastoma: a prospective Children's Cancer Group study. J Clin Oncol. 2000; 18:1260–1268.

5. Evans AE, D'Angio GJ, Propert K, Anderson J, Hann HW. Prognostic factor in neuroblastoma. Cancer. 1987; 59:1853–1859.

6. Joshi VV, Cantor AB, Brodeur GM, Look AT, Shuster JJ, Altshuler G, et al. Correlation between morphologic and other prognostic markers of neuroblastoma. A study of histologic grade, DNA index, N-myc gene copy number, and lactic dehydrogenase in patients in the Pediatric Oncology Group. Cancer. 1993; 71:3173–3181.

7. London WB, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol. 2005; 23:6459–6465.

8. Dhir S, Wheeler K. Neonatal neuroblastoma. Early Hum Dev. 2010; 86:601–605.

9. Fisher JP, Tweddle DA. Neonatal neuroblastoma. Semin Fetal Neonatal Med. 2012; 17:207–215.

10. Fénart D, Deville A, Donzeau M, Bruneton JN. Retroperitoneal neuroblastoma diagnosed in utero. Apropos of 1 case. J Radiol. 1983; 64:359–361.

11. Moppett J, Haddadin I, Foot AB. Neonatal neuroblastoma. Arch Dis Child Fetal Neonatal Ed. 1999; 81:F134–F137.

12. Granata C, Fagnani AM, Gambini C, Boglino C, Bagnulo S, Cecchetto G, et al. Features and outcome of neuroblastoma detected before birth. J Pediatr Surg. 2000; 35:88–91.

13. Gigliotti AR, Di Cataldo A, Sorrentino S, Parodi S, Rizzo A, Buffa P, et al. Neuroblastoma in the newborn. A study of the Italian Neuroblastoma Registry. Eur J Cancer. 2009; 45:3220–3227.

14. Sposto R, London WB, Alonzo TA. Children's Oncology Group. Criteria for optimizing prognostic risk groups in pediatric cancer: analysis of data from the Children's Oncology Group. J Clin Oncol. 2007; 25:2070–2077.

15. Michalowski MB, Rubie H, Michon J, Montamat S, Bergeron C, Coze C, et al. Groupe Neuroblastome de la Société Française d'Oncologie Pédiatrique. Neonatal localized neuroblastoma: 52 cases treated from 1990 to 1999. Arch Pediatr. 2004; 11:782–788.

16. Suh JM, Lee SG, Yoo KH, Sung KW, Koo HH, Kim JY, et al. Outcome of patients with neuroblastoma aged less than 1 year at diagnosis. Korean J Pediatr. 2009; 52:93–98.

17. Blackman SC, Evenson AR, Voss SD, Barnewolt CE, Puder M. Prenatal diagnosis and subsequent treatment of an intermediate-risk paraspinal neuroblastoma: case report and review of the literature. Fetal Diagn Ther. 2008; 24:119–125.